Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep Limited (IMMP) today and set a price target of $7. The company’s shares opened today at $2.49.
McCarthy wrote:
“Immutep announced the dosing of the first patient in the P2 TACTI-002 basket study of its lead asset eftilagimod alpha (‘efti’, LAG-3) with Merck’s (MRK – NR) Keytruda, evaluating the combination in PD-X naïve or refractory patients (lung and head & neck).”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.8% and a 33.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adial Pharmaceuticals Inc, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Immutep Limited is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.21 and a one-year low of $1.70. Currently, Immutep Limited has an average volume of 46.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
